SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
- PMID: 28335783
- PMCID: PMC5364675
- DOI: 10.1186/s12985-017-0708-6
SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
Abstract
Background: Chronic HCV Patients taking PEG-IFN-α/R from different ethnic groups have different probabilities of reaching a sustained viral response (SVR). There are many influence factors, such as HCV genotype, IL-28B single-nucleotide polymorphisms (SNP), Fibrosis 4 index (FIB-4), and aspartate aminotransferase-to-platelet ratio index (APRI) score. But the baseline factors in relation to treatment outcome was still not much clear.
Methods: We evaluated data from 231 chronic HCV patients with or without liver fibrosis and their antiviral efficacy after treatment with pegylated interferon plus ribavirin (PEG-IFN-α/R) for 24-48 weeks. IL-28B SNP and HCV genotypes were analyzed with genome sequencing using pyrosequencing.
Results: Sustained viral response (SVR) rates of patients with HCV 1b and 2a genotypes were 52.25% (58/111) and 75.28% (67/89) (P < 0.01). SVR rates of patients with IL-28B rs8099917 TT, rs12979860 CC and rs12980275 AA were 92.41% (25/27), 92.86% (26/28) and 88.89% (24/27) separately. We found that SVR rates in HCV 1b and 2a patients were only 31.0 and 39.4% if their FIB-4 > 3.25. In addition, when their APRI > 2, only 30.3% of HCV 1b patients and 50.2% of HCV 2a patients could obtain SVR.
Conclusions: There were high proportion of HCV genotype 1b and 2a in Northwest China. In both HCV 1b and 2a genotypes, patients with protective-genotype of IL-28B were more likely to obtain SVR. However, those with significant fibrosis or cirrhosis were less likely, no matter their genotype. Combined factors of HCV genotype, IL-28B genotype, FIB-4 and ARPI may indicate high prediction and clinical value regarding treatment with PEG-IFN-α/R and prognostic evaluation of chronic hepatitis C patients.
Keywords: Chronic hepatitis C; Cirrhosis; HCV subtype; Individualization; Interleukin 28; Single nucleotide polymorphism.
Figures


Similar articles
-
Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.World J Gastroenterol. 2017 Jun 7;23(21):3815-3824. doi: 10.3748/wjg.v23.i21.3815. World J Gastroenterol. 2017. PMID: 28638221 Free PMC article.
-
Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):745-54. doi: 10.1007/s10096-012-1799-z. Epub 2013 Jan 13. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23314745 Free PMC article.
-
Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16. Aliment Pharmacol Ther. 2012. PMID: 22591106
-
Association of Interleukin 28B Polymorphism with Clearance of Hepatitis C Virus: A Mini Review.Crit Rev Eukaryot Gene Expr. 2020;30(3):223-229. doi: 10.1615/CritRevEukaryotGeneExpr.2020029692. Crit Rev Eukaryot Gene Expr. 2020. PMID: 32749108 Review.
-
Predictive power of Interleukin-28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis.Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101480. doi: 10.1016/j.clinre.2020.06.006. Epub 2020 Jul 1. Clin Res Hepatol Gastroenterol. 2021. PMID: 32622719
Cited by
-
Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.Cells. 2019 Apr 5;8(4):317. doi: 10.3390/cells8040317. Cells. 2019. PMID: 30959825 Free PMC article. Review.
-
Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy.Cureus. 2020 Nov 19;12(11):e11565. doi: 10.7759/cureus.11565. Cureus. 2020. PMID: 33364092 Free PMC article.
-
Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.Front Public Health. 2021 Dec 9;9:779215. doi: 10.3389/fpubh.2021.779215. eCollection 2021. Front Public Health. 2021. PMID: 34957030 Free PMC article.
-
Efficacy and Safety of Sofosbuvir and Ribavirin for Treating Chronic Hepatitis C, Genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan.Cureus. 2019 Apr 14;11(4):e4458. doi: 10.7759/cureus.4458. Cureus. 2019. PMID: 31205844 Free PMC article.
-
Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study.Medicine (Baltimore). 2024 Feb 16;103(7):e37212. doi: 10.1097/MD.0000000000037212. Medicine (Baltimore). 2024. PMID: 38363923 Free PMC article.
References
-
- Antonelli A, Pistello M. New Therapies, Markers and Therapeutic Targets in HCV Chronic Infection, and HCV Extrahepatic Manifestations. Curr Drug Targets. 2015. - PubMed
-
- Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, et al. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterol. 2012;12:162. doi: 10.1186/1471-230X-12-162. - DOI - PMC - PubMed
-
- Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–523. doi: 10.1016/S0140-6736(13)62121-2. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources